Great presentation from @jrzalcberg on the access to #biomarker testing in #Asia. It is important to increase access to testing which can positively impact patients outcomes. #bettertesting #ESMOAsia23

2,5 days of very interesting discussions on the use and future direction of #liquidbiopsy @isliquidbiopsy .@UmbertoMalapel1 .@drgandara @MJOSESERRANO19 @ChristianRolfo @ElJanLe @MCristofanill

RT @DrYukselUrun: Dr. Masahiro Tsuboi 🇯🇵 has highlighted the future of early lung cancer detection with a focus on a miRNA biomarker panel,….

RT @DrYukselUrun: The EMPower-Lung 1 Study design presents a novel approach to NSCLC treatment.🧬🧬early ctDNA changes at 3 weeks correlate h….

RT @pashtoonkasi: 🩸#ISLB23 So glad to be present at the kickoff of @isliquidbiopsy 2023, Madrid, Spain.🇪🇸. Nothing better than focusing on….

In order to correct identify patients we need more testing!.All room in agreement with @ChristianRolfo. #bettertesting #ESMO2023

Breathtaking presentation of @dplanchard on the future of #ADC treatment in #lung cancer. Looking forward to the future with personalised ADC

#TKI and #chemotherapy are not for all #NSCLC patients. More time should be spent on the #NGS and #biomarker results to better decide the treatment decisions. Great insight from @JulienMazieres .#bettertesting.

Overview of resistance pathways for TKI treatments in lung cancer by @JulienMazieres during the 4th joint meeting Lung Cancer in Nice. #bettertesting

Federico Rojo on the importance of the pre-analytical phase for the outcome of #NGS and the impact on correctly identifying #cancer #patients .#bettertesting

Great insight and positioning from Roberto Salgado. We as a collective should change how we face #CDx and work on developing assays that address a biological question and not only to be validated by a trial. #ESPCongress 2023

Good morning Chicago. It is great to be back and already warming up for #ASCO23 looking forward to meeting old and new friends and contributing toward improving biomarker testing. #bettertesting #biomarker #oncology

Very nice talk from @BenWestphalen on the incorporation of AI as a way to complement and democratise access to diagnostics. #bettertesting

RT @fundacion_ff: Aquí 👉👉Jornada Mesa 2: #PrecisionMedicine en #España desde la perspectiva del uso de #biomarcadores - Actividades actuale….

It is necessary to create more initiatives where different stakeholders in precision medicine can talk and become a source of knowledge. #PrecisionMedicine in #Spain with Fernando Vidal, Domènec Puig and Javier Losa. #bettertesting #biomarker

Great data presented by @NReguart on the impact of the use of I/O with chemo in first line: there is an increase of 100% on the use of I/O in 1L between 2020 and 2021. Great impact for patients. #ESMO2022 @myESMO.

Initial data on the resistance of #KRAS inhibitors by Dr Jürgen Wolf @myESMO #ESMO2022

High variability of #biomarkers tested in Europe. Following international guidelines instead of national would allow for more homogenous access according to Dr. Hofman. #ECPBasel2022

Using cell lines for #Her2 low expressors is an important tool to support pathologists on identifying challenging cases. Talk from Dr. Lebeau. #ECP2022 @IAPCentral

One image is worth more than a 1000 words. Great talk by Into Zlobec on the challenges for training #AI algorithms in #DigitalPathology #ECP2022